Market capitalization | €1.35b |
Enterprise Value | €1.26b |
P/E (TTM) P/E ratio | 2,141.64 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.53 |
P/S ratio (TTM) P/S ratio | 8.08 |
P/B ratio (TTM) P/B ratio | 7.32 |
Dividend yield | 0.86% |
Last dividend (FY23) | €0.65 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Pharma Mar forecast:
6 Analysts have issued a Pharma Mar forecast:
Sep '24 |
+/-
%
|
||
Revenue | 167 167 |
3%
3%
|
|
Gross Profit | 158 158 |
1%
1%
|
|
EBITDA | 0.43 0.43 |
94%
94%
|
EBIT (Operating Income) EBIT | -5.71 -5.71 |
1,296%
1,296%
|
Net Profit | 0.62 0.62 |
96%
96%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Head office | Spain |
CEO | José Sousa-Faro |
Founded | 1986 |
Website | www.pharmamar.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.